Yes, there are real contraindications, but the list is shorter and more specific than many women are led to believe, and much of what gets treated as an automatic no is actually a relative, individualized consideration rather than an absolute one.
Guideline-level frameworks, including The Menopause Society's 2022 position statement, describe a small set of situations where systemic hormone therapy should not be started at all: current or past hormone-receptor-positive breast cancer, undiagnosed vaginal bleeding that has not been evaluated, an active or very recent blood clot, stroke, or heart attack without an established anticoagulation plan, active liver disease, and known or suspected pregnancy. Everything else that commonly comes up in these conversations, a blood clot years in the past, a mother or sister with breast cancer but no known genetic mutation, certain inherited clotting tendencies, is generally treated as a factor that changes the conversation, the formulation, or the delivery route rather than one that ends it. Route matters here: oral and transdermal estrogen do not carry an identical risk profile for clotting, so what looks like a firm no with one delivery method may be a reasonable option with another after individualized assessment. What the evidence does not establish is a one-size-fits-all answer for any of the relative categories; those decisions depend on details specific to each woman's history that only a clinician reviewing her full record can weigh.
There is a real tension between clinicians who default to caution and treat almost any relevant personal or family history as disqualifying, and menopause specialists who argue for individualized, route- and dose-aware risk assessment backed by specialist-center data.
What the research shows, and which source each finding rests on
The current guideline-level framework used by major menopause and endocrine societies separates absolute contraindications to systemic hormone therapy from relative ones. Both The Menopause Society's 2022 position statement and the Endocrine Society's clinical practice guideline direct clinicians to screen for cardiovascular and breast cancer risk before initiating treatment, then individualize the decision using the hormone type, dose, duration, route of administration, and timing of initiation as modifying factors rather than treating every risk factor identically.
Per current guideline-level frameworks, the absolute contraindications, meaning situations where hormone therapy should not be started at all, include current or past hormone-receptor-positive breast cancer, undiagnosed vaginal bleeding that has not undergone workup, an active or recent venous or arterial thromboembolic event (blood clot, stroke, or heart attack) without an established anticoagulation plan, active liver disease, and known or suspected pregnancy. These are presented as reasons hormone therapy should not be used, not as points for negotiation.
A systematic review and meta-analysis of observational studies found that, compared with transdermal estrogen, oral estrogen was associated with an increased risk of a first venous thromboembolism (RR 1.63, 95% CI 1.40-1.90) and roughly twice the risk of deep vein thrombosis specifically (RR 2.09, 95% CI 1.35-3.23). This means the delivery route itself changes the risk calculation for some contraindications, rather than the underlying diagnosis alone determining eligibility.
A personal history of venous thromboembolism is generally categorized as a relative, individualized contraindication rather than an absolute one. Clinical reviews describe a framework in which the type of prior clot, whether it was provoked, thrombophilia testing results, and hematology input determine whether transdermal estrogen, which does not appear to raise venous thromboembolism risk to the same degree as oral estrogen, can be considered, sometimes alongside anticoagulation. A single specialist center's case series of 115 women with a personal history of venous or arterial thromboembolism (81% prior VTE, 19% prior arterial event, 20% on lifelong anticoagulation) who were started on hormone therapy containing transdermal estradiol found no recurrent thromboembolic event over a minimum 12-month follow-up (patients had generally been using this transdermal therapy for longer, an average of about three years, but the recurrence outcome itself was tracked for at least 12 months). This is reassuring observational evidence from one specialist clinic, not a randomized trial, and it does not establish that the treatment is risk-free for any given woman.
A family history of breast cancer without a known pathogenic mutation is treated differently in risk-stratification frameworks than a personal history of breast cancer or a confirmed genetic mutation, and is generally categorized as a relative, individualized consideration rather than an automatic absolute contraindication.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
When in doubt, say no
many generalist and primary-care clinicians, shaped by a cautious post-WHI reading of the evidence
Because the original Women's Health Initiative trials found increased breast cancer and cardiovascular risk with a specific oral estrogen-progestin combination, and because formal thrombophilia testing and specialist risk stratification are not always available in a routine visit, many clinicians default to withholding hormone therapy whenever a personal or family history touches breast cancer or clotting. This is treated as the safer, more defensible position even where specialist guidance would allow an individualized route- or dose-based option.
Individualize by route, dose, and testing
menopause specialists and Menopause Society-certified practitioners, informed by specialist-center data
Specialist menopause services argue that blanket exclusion is not supported by current data: a single specialist center's case series of 115 women with a personal history of venous or arterial thromboembolism found no recurrence over a minimum 12-month follow-up using transdermal estradiol (average duration of use in the cohort was about three years), often with hematology input and thrombophilia testing. Route-specific meta-analysis data show transdermal estrogen does not raise venous thromboembolism risk the way oral estrogen does, so the recommendation should be individualized risk assessment rather than automatic exclusion.
What would settle it: Larger, prospective, multi-center studies (randomized where ethically feasible) following women with a personal history of thromboembolism, thrombophilia, or a family history of breast cancer who use hormone therapy, with long-term recurrence and cancer-incidence data, rather than the current mix of registry data, single-center case series, and extrapolation from general-population meta-analyses.
What is really going on here
- Does this specific reason belong on the short list of absolute contraindications, or is it being treated as absolute when the guidance actually calls it relative?
- Would a different route, dose, or hormone type change the risk-benefit balance in this particular case?
- Is the evidence behind a 'you can't' answer a large trial, a small case series, or just general caution?
Questions for your doctor
- Based on my personal and family history, which of these are absolute reasons not to start hormone therapy, and which are relative factors we can weigh together?
- Would a transdermal patch, gel, or spray change the recommendation compared with an oral tablet, given my history?
- Do I need thrombophilia testing, a hematology referral, or additional evaluation before we make this decision?
- If hormone therapy genuinely isn't right for me, what are the evidence-based non-hormonal options for what I'm dealing with?
Questions with no answer yet
How well does the reassuring safety signal for transdermal estradiol in women with a personal history of thromboembolism generalize beyond a single specialist center's case series?
Limited evidence, single-centerWhat is known: One UK case series of 115 women with a personal history of venous or arterial thromboembolism found no thrombotic recurrence over a minimum 12-month follow-up using transdermal estradiol (average duration of use in the cohort was about three years), most with specialist hematology involvement. Broader population meta-analyses show transdermal estrogen does not raise venous thromboembolism risk the way oral estrogen does, but that general data comes from women without a personal clotting history.
What would test it: A larger, multi-center, prospective cohort or registry specifically enrolling women with a documented personal history of thromboembolism or confirmed thrombophilia who use transdermal hormone therapy, with standardized anticoagulation protocols and long-term recurrence tracking.
What is the actual, quantified breast cancer risk from hormone therapy in a woman with a family history of breast cancer but no known pathogenic mutation, as distinct from a woman with no family history or a woman with a confirmed mutation?
Not separately quantified in the literature reviewedWhat is known: Guideline frameworks stratify risk differently for personal history, mutation-confirmed history, and family history alone, treating family history without a known mutation as a less severe, individualized consideration. A precise, separately quantified risk figure specific to this subgroup was not identified in this review.
What would test it: A dedicated prospective cohort or case-control study stratifying hormone therapy users by family history status and confirmed genetic testing results, reporting breast cancer incidence separately for each subgroup.
Sources
- 1.The 2022 hormone therapy position statement of The North American Menopause Society.The 2022 hormone therapy position statement of The North American Menopause Society, Menopause 2022 · Systematic review or guideline
- 2.Stuenkel CA et al., Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab 2015Not rated
- 3.Morris G, Talaulikar V, Hormone replacement therapy in women with history of thrombosis or a thrombophilia, Post Reprod Health 2022Not rated
- 4.Howells P et al., The use of HRT containing transdermal estradiol in women with a personal history of venous or arterial thromboembolism, Post Reprod Health 2025Not rated
- 5.Mohammed K et al., Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis, J Clin Endocrinol Metab 2015Not rated
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- Is there a test for perimenopause?
- Why did my doctor say my hormones are normal, when I feel terrible?
- How many doctors do women typically see before someone finally tells them it's perimenopause?
- I read that most women with menopause symptoms never seek help - is that really true?
- If there's no blood test, how is perimenopause actually diagnosed?
- What about AMH testing - can that tell me when I'll hit menopause?
- Back to topic: Spotting perimenopause, hormone testing and the care gap